Compare
Pit 2–4 stocks against each other: U-Score, pillars, fundamentals, and normalized price history. Same universe, same methodology, one view.
| Metric | VALIANTLAB Valiant Laboratories Limited Pharma · Small | NECLIFE Nectar Lifesciences Limited Pharma · Small | LYKALABS Lyka Labs Limited Pharma · Small | KILITCH Kilitch Drugs (India) Limited Pharma · Small |
|---|---|---|---|---|
| Final Score | 15 | 28 | 22 | 53 |
| Verdict | OVERVALUED | OVERVALUED | OVERVALUED | FAIR VALUE |
| Style | OVERVALUED | OVERVALUED | OVERVALUED | Growth at Value |
| Piotroski | 4/9 | 4/9 | 6/9 | 8/9 |
| Valuation | 3/30 | 5/30 | 5/30 | 14/30 |
| Growth | 2/25 | 4/25 | 6/25 | 22/25 |
| Quality | 0/20 | 0/20 | 0/20 | 1/20 |
| Balance Sheet | 11/15 | 11/15 | 7/15 | 9/15 |
| Cash Flow | 1/10 | 9/10 | 4/10 | 2/10 |
| Price | ₹72.82 | ₹11.83 | ₹70.05 | ₹187.01 |
| P/E | 72.40 | — | — | 19.40 |
| P/B | 1.25 | 0.39 | 2.46 | 2.09 |
| ROE | 2.00% | -7.46% | -10.20% | 12.50% |
| ROCE | 2.54% | -4.88% | -6.10% | 14.40% |
| Debt / Equity | 0.00 | 0.00 | 0.53 | 0.32 |
| FCF Yield | — | 380.09% | — | — |
| Dividend Y | — | — | — | — |
| Altman Z | 5.48 | 4.68 | 2.96 | 3.72 |
| Promoter % | 74.94% | 51.84% | 58.16% | 14.00% |
| Mkt Cap (₹Cr) | 402.00 | 226.00 | 227.00 | 584.00 |
| Graham # | ₹36.77 | — | — | ₹124.64 |
| Fair PE | 1.7 | 5.8 | 8.7 | 42.0 |
| MoS % | -4074.8% | — | — | +48.4% |
Normalized price (3-year, indexed to 100)
Higher line = better relative performance from startVALIANTLAB64
NECLIFE32
LYKALABS47
KILITCH61